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Abstract
Introduction The stromal microenvironment has a profound
influence on tumour cell behaviour. In tumours, the extracellular
matrix (ECM) composition differs from normal tissue and allows
novel interactions to influence tumour cell function. The ECM
protein tenascin-C (TNC) is frequently up-regulated in breast
cancer and we have previously identified two novel isoforms –
one containing exon 16 (TNC-16) and one containing exons 14
plus 16 (TNC-14/16).
Methods The present study has analysed the functional
significance of this altered TNC isoform profile in breast cancer.
TNC-16 and TNC-14/16 splice variants were generated using
PCR-ligation and over-expressed in breast cancer cells (MCF-7,
T47D, MDA-MD-231, MDA-MB-468, GI101) and human
fibroblasts. The effects of these variants on tumour cell invasion
and proliferation were measured and compared with the effects
of the large (TNC-L) and fully spliced small (TNC-S) isoforms.
Results TNC-16 and TNC-14/16 significantly enhanced tumour
cell proliferation (P < 0.05) and invasion, both directly (P <
0.01) and as a response to transfected fibroblast expression (P
< 0.05) with this effect being dependent on tumour cell
interaction with TNC, because TNC-blocking antibodies
abrogated these responses. An analysis of 19 matrix
metalloproteinases (MMPs) and tissue inhibitor of matrix
metalloproteinases 1 to 4 (TIMP 1 to 4) revealed that TNC up-
regulated expression of MMP-13 and TIMP-3 two to four fold
relative to vector, and invasion was reduced in the presence of
MMP inhibitor GM6001. However, this effect was not isoform-
specific but was elicited equally by all TNC isoforms.
Conclusions These results demonstrate a dual requirement for
TNC and MMP in enhancing breast cancer cell invasion, and
identify a significant role for the tumour-associated TNC-16 and
TNC-14/16 in promoting tumour invasion, although these
isoform-specific effects appear to be mediated through MMP-
independent mechanisms.
Introduction
Cellular interactions with the extracellular matrix (ECM) are
critical in the modulation of cell growth, migration, invasion and
tissue-specific gene expression [1-3]. The ECM around
tumours differs markedly from that in normal tissues [4,5] and
therefore is likely to deliver different signals to tumour cells,
BSA: bovine serum albumin; CM: conditioning medium; ECM: extracellular matrix; EGF: epidermal growth factor; ELISA: enzyme-linked immunosorb-
ent assay; ER: oestrogen receptor; DMEM: Dulbecco's modified Eagle's medium; FBS: fetal bovine serum; FN III: fibronectin type III-like repeats; 
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which will impact on their behaviour. One of the most consist-
ent changes in the ECM of many solid tumours is up-regulation
of the matrix glycoprotein, tenascin-C (TNC) [6-8]. TNC is a
complex multifunctional protein, which has been shown to pro-
mote cell migration, inhibit focal contact formation, promote
angiogenesis and, in some systems, act as a cell survival factor
[9-11]. Each TNC subunit consists of an N-terminal tenascin
assembly region, 14.5 epidermal growth factor-like (EGF)
repeat domains, a variable number of fibronectin type III-like
repeats (FN III) and a C-terminal fibrinogen-like domain [12]
(Figure 1). Multiple isoforms of TNC can be generated through
alternative splicing of nine FN III repeats between conserved
repeats 5 and 6 (exons 9 and 17) at the pre-mRNA level and
these may have differing effects. For example, in the develop-
ing mouse central nervous system, up to 27 distinct splice var-
iants have been identified and are expressed in a strict
temporal-spatial manner supporting a role for these variants in
specific neurone-glia interactions [13]. A number of studies
have shown that specific functions are mediated by distinct
domains of TNC [10,11,14] and there is growing evidence to
indicate that the biological function of TNC is dependent on
the splicing pattern [15]. This raises the possibility that
tumour-associated stroma can generate novel interactions
with tumour cells through the expression of different TNC
splice variants. In keeping with this, changes in the pattern of
TNC isoform expression have been described in a number of
malignancies [16-18], the nature of which appears to be
tumour-type specific.
Previously, we have identified two TNC isoforms that consist-
ently and specifically are up-regulated in invasive breast carci-
noma as well as in a subset of pre-invasive ductal carcinoma
in-situ: one containing exon 16 (TNC-16) the other containing
exon 14 plus 16 (TNC-14/16) [19]. Up-regulation of these iso-
forms has also been reported in ovarian carcinoma [20]; how-
ever, their effect on tumour cell behaviour has not been
established.
A further consistent change in the tumour stromal environment
is up-regulation of proteolytic enzymes, particularly members
of the matrix metalloproteinase (MMP) family. Overexpression
of several MMPs has been described in breast cancer [21,22]
and both in-vitro and in-vivo systems demonstrate a role for
MMP in mediating breast cancer cell invasion [23,24]. Regu-
lation of MMP expression and activity is complex, and may be
mediated through naturally occurring tissue inhibitors of MMP
(TIMP) or by direct regulation of gene expression. Several
studies have indicated a role for TNC in regulating MMP gene
expression [25-27].
The aim of this study was to investigate directly the effects of
tumour-associated TNC-16 and TNC-14/16 isoforms on
Figure 1
Schematic diagram of tenascin-C Schematic diagram of tenascin-C. The domain structure of tenascin-C comprising N-terminal tenascin assembly (TA) domain followed by 14.5 epi-
dermal growth factor (EGF)-like repeats, the fibronectin type III (FN III)-like repeats and the carboxy fibrinogen-like domain. The FN III region consists 
of eight conserved repeats, designated 1 to 8, and up to nine alternatively spliced FN III repeats designated as letters A to D, AD1 and AD2 (shown 
in shading). The exon organisation of the tenascin-C gene is shown below.Available online http://breast-cancer-research.com/content/11/2/R24
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breast cancer cell behaviour and to determine whether these
isoforms modulate tumour cell behaviour through regulation of
MMP.
Materials and methods
Cell lines and primary cells
Breast cancer cell lines (MCF-7, T47D, MDA MB 231, ZR-75-
1, MDA MB 468, GI101, MDA MB 436, HS578T, SkMel 28)
and the human fetal foreskin fibroblast cell line hfff2 were
obtained from ATCC (American Type Culture Collection, Man-
assas, VA, USA). Primary normal breast tissue was obtained
following Ethics Approval and informed patient consent
(Leicestershire, LREC 7054). Fibroblasts were isolated from
reduction mammoplasty specimens and purity confirmed as
previously described [28]. All cells were maintained in Dul-
becco's modified Eagle's medium (DMEM) plus 2 mM L-
glutamine and 10% FBS.
TaqMan real-time PCR analysis of endogenous tenascin-
C expression
Taqman real-time PCR (Applied Biosystems, Foster, CA,
USA) was applied to survey different exons in breast cell lines.
An inventoried assay was available for the TNC invariant exon
17/18 boundary (Applied Biosystems Taqman Assay,
Hs01115654_m1) and hypoxanthine phosphoribosyltrans-
ferase 1 (HPRT1) (Applied Biosystems Taqman Assay,
Hs99999909_m1) as a housekeeping gene. Primers and
probe were developed in house for 9/16 and 14/16 exon
boundaries. For the inventoried Taqman assays, 4 μl of cDNA
(diluted 1:10) was analysed in a reaction containing 0.5 μl of
probe, 0.5 μl Ultrapure water and 5 μl of 2 × Taqman Fast
PCR mastermix. For the 9/16 and 14/16 assays, 3.6 μl of
cDNA (diluted 1:10) was analysed in a reaction containing 0.2
μl of probe, 0.6 μl of each primer and 5 μl of 2 × Taqman Fast
PCR mastermix. Normalised relative expression was deter-
mined by comparison with standard curves derived from TNC
9–16 and TNC 9–14–16 recombinant clones to correct for
differences in PCR efficiency for each TNC probe set and the
level of housekeeping gene expression was used to correct for
any differences in cellularity.
Generation of tenascin-C isoforms
TNC splice variant cDNAs containing either exon 16 or exons
14 and 16 were prepared by ligation and nested PCR using
cloned human TNC cDNA for the large, unspliced isoform
TNC-L (pNUT-HxB.L) and the truncated isoform TNC-S
(pNUT-HxB.S) [29].
Primers designed across exon boundaries 9–16, 9–14 and
14–16 were used to amplify flanking DNA to include the
restriction sites Bcl1  and  Sfi1  with  bcl1ten1 and sfi1ten1
(Table 1 and Figure 2). These enzymes cut uniquely within
exon 9 and 17 of the TNC cDNA. The amplicons were purified
by Qiagen column (Sussex, UK) and ligated by nested PCR
using bcl1ten2 and sfi1ten2 internal primers. The ligated DNA
fragments were cloned into TOPO vector pcDNA3.1/V5/His-
TOPO, screened by PCR for recombinants and sequenced.
The Bcl1 and Sfi1 fragments for each spliced variant were re-
cloned into TNC-S sequence in the mammalian expression
vector pCMVscript and pCMV-tag4a (Invitrogen Life Science,
Carlsbad, CA, USA) to produce pTNC-16 and pTNC-14/16.
At each stage, all clones were confirmed by sequencing.
Clones were tagged with Flag sequence to allow detection of
the expressed protein.
Transfection of cell populations
The breast cancer cell lines MCF-7, T47D, MDA-MB 231,
MDA-MB-468 and GI101, the fibroblast cell line hfff2 and pri-
mary normal breast fibroblasts from a series of donors were
transiently transfected with TNC-16, TNC-14/16, TNC-L,
TNC-S or vector only using Genejuice Transfection Reagent
(Novagen, Darmstadt, Germany) according to the manufac-
turer's instructions. In some experiments, TNC clones were
transfected in combination using the same approach. Expres-
sion was confirmed by RT-PCR using the primer set 8F/18R
spanning the entire alternatively spliced region (Table 1) and
immunohistochemistry using the anti-Flag M2 antibody
(Sigma, Dorset, UK), anti-TNC with BC-24 at 1:7500 for all
isoforms and α IIIB at 1:1000 for isoforms containing exon 14
and a standard Avidin-Biotin Alkaline Phosphatase detection
system. Equal transfection efficiencies for each isoform were
confirmed by estimating the proportion of cells that immunos-
tained positive.
Western blotting
Levels of cellular and secreted TNC isoforms were determined
by western blotting of transfected cell lysates and conditioned
media (CM) respectively. Cells were transiently transfected
and incubated for 24 hours, serum-free media was added and
CM was collected after a further 48 hours. Cell lysates were
harvested in gold lysis buffer containing a protease inhibitor
cocktail (Sigma, Dorset, UK) 48 hours after transient transfec-
tion. Protein concentrations were quantified on a Lambda 25
UV/VIS spectrophotometer at 750 nm using the BSA protein
assay, then equal amounts of protein were loaded onto 6%
SDS-PAGEs and transferred to Hybond ECL nitrocellulose
membrane (Amersham Biosciences, Buckinghamshire, UK).
Membranes were blocked in Tris-buffered saline, 5% milk and
1% Tween for one hour and then probed for two hours with a
rabbit polyclonal TNC antibody (clone H300, recognising all
forms of TNC; Santa-Cruz, California, USA). A secondary anti-
body, donkey anti-rabbit HRP-linked IgG, 1:2000 (Amersham
Biosciences, Buckinghamshire, UK), was added for one hour
and blots were detected using an enhanced chemilumines-
cence detection kit (Amersham Biosciences, Buckingham-
shire, UK).
Analysis of tumour cell invasion
Measurement of tumour cell invasion was based on modified
Boyden chamber assays as described previously [28]. ToBreast Cancer Research    Vol 11 No 2    Hancox et al.
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measure the direct effect of TNC isoform expression on
tumour cell invasion, the transfected tumour cell population
was placed in the upper chamber of the assay and a 1:1 ratio
of serum-free DMEM and hfff2 CM added to the lower cham-
ber to act as a chemotactic stimulus. CM was generated from
hfff2 cells at 70% confluence, after 48 hours culture under
serum-free conditions, and the media was then removed and
centrifuged to remove any cell debris. To measure the indirect
effect of fibroblast-associated expression of TNC on tumour
cell invasion, either transiently transfected primary fibroblasts
were placed in the lower well of the assay at 1 × 105 cells per
well, or CM, generated from transfected fibroblasts as
described above, was added to the lower chamber of the inva-
sion assay.
The invasion assays were run over 48 hours and performed in
duplicate a minimum of three times for all conditions. For each
assay chamber, 20 representative fields were counted on a
Leica microscope at × 200 magnification and the percentage
mean invasion index (MII) calculated using the number of cells
on the bottom compared with the total number of cells on the
top and bottom surfaces multiplied by 100 and averaged for
each experiment.
Figure 2
PCR-ligation strategy for generation of TNC-16 and TNC-14/16 clones PCR-ligation strategy for generation of TNC-16 and TNC-14/16 clones. (a) Primers designed incorporating unique restriction sites were used to link 
exons 9 to 16 in a three-step polymerase chain reaction (PCR)-mediated ligation strategy. This allowed directional cloning from the Bcl1 and Sfi1 
sites into the TNC-S sequence and this sequence was subsequently transferred into the mammalian expression vector pCMV script. The gel image 
shows exon 9 and exon 16 products and the combined 9–16 amplicon. (b) The same PCR-mediated ligation strategy was used to link exons 9, 14 
and 16 prior to directional cloning into the TNC-S sequence for expression. The gel image shows the multi-step process used to link exons 9, 14 
and 16.Available online http://breast-cancer-research.com/content/11/2/R24
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I n  s o m e  e x p e r i m e n t s ,  b l o c k i ng antibody to TNC (BC-24,
Sigma, Dorset, UK), IgG1 control (Dakocytomation, Glostrup,
Denmark) or a broad-spectrum MMP inhibitor (GM6001,
Chemicon, Watford, UK) were included. The TNC antibody
BC-24 was desalted to remove sodium azide before use by
passing through a PD-10 Sephadex G-25 column (GE Health-
care, Buckinghamshire, UK). Both BC-24 and IgG1 control
were included in the upper and lower wells of the assay at 1
ng/ml final concentration. GM6001 was included at 10 nM.
Analysis of tumour cell proliferation
The direct and indirect effects of TNC isoforms on tumour cell
proliferation were assessed on the basis of BrdU incorpora-
tion. Tumour cells were transfected, as described above, and
cultured on poly-d-lysine coated coverslips for 72 hours under
serum-free conditions. BrdU was added to the media at a con-
centration of 5 mM for the final three hours. The cells were
fixed and incorporated BrdU localised using anti-BrdU
(Bu20a; Sigma, Dorset, UK) and a standard Avidin-Biotin
detection system. The mean proliferation index of three assays
was calculated by averaging the number of stained cells as a
percentage of the total number of cells (minimum of 1000 cells
over at least 10 high power fields) for each assay. To measure
the indirect effect of fibroblast-associated TNC on tumour cell
proliferation, fibroblast populations were transfected as previ-
ously described, the CM harvested and added to tumour cells.
Proliferation was then assessed as described above.
Analysis of matrix metalloproteinase expression and 
activity
TaqMan real-time PCR analysis of the effect of TNC 
isoforms on expression profile of MMP and TIMP
TaqMan real-time PCR was carried out as previously
described on mRNA isolated from MCF-7 breast cancer cells
and hfff2 fibroblasts transfected with different TNC clones,
compared with vector-only and non-transfected control popu-
lations [30]. Analysis was performed on mRNA from three sep-
arate experiments and included measurement of 19 MMPs
[3,6,7,9-18,20,22-25] and TIMP 1 to 4.
ELISA
For selected MMPs, levels of enzyme activity were measured
by ELISA. Invasion assays were set up to include MCF-7 cells
transfected with different TNC clones or CM from TNC-trans-
fected hfff2 fibroblasts and cultured for 48 hours, as previously
described. End-of-assay medium was collected from the
assays, protein levels measured and equal concentrations
applied to ELISA plates for MMP-1, MMP-2 and MMP-9
(Amersham, Buckinghamshire, UK). Each experiment was per-
formed in triplicate.
Zymography
Levels of enzyme activity were also measured by substrate gel
zymography. End-of-assay medium was collected from assays
containing cells transfected with different TNC clones, as
described above. SDS-PAGE substrate gels were made by
incorporating Gelatin (Bloom 300, Sigma, Dorset, UK) in a
10% acrylamide separating gel at a final concentration of 1
mg/ml. To each gel, samples containing equal amounts of pro-
tein (as determined by BCA protein assay) were mixed with
non-reducing sample buffer (62.5 mM Tris-HCl (pH 6.8), 10%
glycerol, 2% SDS, 0.1% bromophenol blue) and added to the
gel without boiling. MMP-9 recombinant pro-enzyme (Calbio-
chem, California, USA) and molecular weight markers were
run on each gel. Following electrophoresis, gels were washed
twice in 2.5% Triton X-100 for 30 minutes at 37°C to remove
the SDS. Gels were incubated at 37°C overnight in develop-
ing buffer containing 50 mM Tris-HCl, 0.2 M sodium chloride,
5 mM calcium chloride and 0.02% Triton X-100. Gels were
stained with 0.5% coomassie blue G250 in 30% methanol,
10% glacial acetic acid for 30 minutes and de-stained in the
same solution without coomassie blue. Gelatin-degrading
enzymes were identified as clear bands against the blue back-
ground of the stained gel. Images of stained gels were cap-
tured under illumination using the UVP Imagestore 5000
(Ultra-Violet Products, Cambridge, UK). Direct comparisons
between separate gels were not made, because the intensity
of background staining was variable. Experiments were
repeated a minimum of three times.
Statistical analysis
Statistical analysis was performed using the SPSS 12.0 sta-
tistics package (Chicago, IL, USA). For comparison between
Table 1
PCR primer sequences
Primers Sequence 5'-3'
T8-F CAATCCAGCGACCATCAACG
T18-R CGTCCACAGTTACCATGGAG
T9-16F GCATCCACTGAAGCCGAACCGGAAGTTGAC
T9-16R GGTTCGGCTTCAGTGGATGCCTTCACATGT
T9-14F GCATCCACTGCCAAAGAACCTGAAATTGGA
T9-14R GGTTCTTTGGCAGTGGATGCCTTCACATGT
T14-16R GGTTCGGCTTCTGTCGTGGCTGTGGCACTG
T14-16F GCCACGACAGAAGCCGAACCGGAAGTTGAC
Bcl1ten1 GCCAGATCGAGGTGAAAGATGTCACA
Bcl1ten2 GGTGACCACCACACGCTTGGATG
Sfi1ten1 CTTCTGAGTCAGTGATGTTGGCTGTCACC
Sfi1ten2 GGCAATGGCTGGCTGCCACCT
Details of polymerase chain reaction (PCR) primers used for the 
generation of specific tenascin-C isoforms and to analyse expression 
of tenascin-C alternatively spliced forms.Breast Cancer Research    Vol 11 No 2    Hancox et al.
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different TNC isoforms the one-way analysis of variance test
was used. A Bonferroni correction was applied to all post-hoc
analyses and a P value of less than 0.05 was considered sig-
nificant.
Results
Endogenous expression of tenascin-C isoforms in breast 
cancer cells
Real-time PCR for endogenous TNC isoform expression was
performed on a series of breast cancer cell lines. This showed
that MCF-7, T47D and ZR-75-1 cell lines do not express
detectable levels of TNC or its isoforms, while GI-101,
Hs578T, MDA MB 231, MDA MB 436 and MDA MB 468 cells
all express TNC. Furthermore, all express TNC-14/16 and GI-
101, MDA 436 and MDA MB 468 also express TNC-16 (Fig-
ure 3a).
Expression of tenascin-C isoforms in breast cancer cells 
and fibroblasts
The breast cancer cells MCF-7, T47D, MDA MB 231, MDA
MB 468 and GI101, the hfff2 fibroblast cell line and a series
(n = 5) of primary normal breast fibroblasts were transiently
transfected with clones for TNC-S, TNC-L, TNC-16 and TNC-
14/16 and vector only controls. Expression of specific iso-
forms was confirmed by RT-PCR (Figure 3b), and protein
expression was confirmed by immunohistochemistry to the
Flag tag (Figure 3c), which demonstrated an average transfec-
tion efficiency of 35% for each isoform. No native TNC was
detected in MCF-7 cells (Figure 3c, right image). The level of
expression in transfected MCF-7 cells was equivalent to that
seen endogenously in MDA-MB-231 cells (unpublished data).
Western blotting of cell lysates (Figure 3d, i) and CM (Figure
3d, ii) demonstrated equivalent levels of TNC protein expres-
sion from each of the clones, and confirmed the presence of
TNC.
Direct effects of tenascin-C isoforms on tumour cell 
behaviour: effect on invasion and proliferation
The breast cancer cell lines exhibited different levels of inva-
sion. The MCF-7, T47D and MDA MB 468 cell lines showed
low level invasion (Mean Invasion Index (MII) of 8%, 2% and
6%, respectively) whereas the MDA-MB-231 and GI101 cell
lines exhibited high invasion (MII of 27% and 23% respec-
tively; Figure 4a). For cell lines transfected with either the vec-
tor alone or TNC-S there was no significant change in the MII
compared with the untreated cells (Figure 4a). TNC-L trans-
fectants in MDA-MD-231 and T47D showed increased MII
over baseline levels (P = 0.005 and P = 0.011, respectively).
However, the highest levels of invasion were observed for
each of the cell lines when transfected with TNC-14/16 (P <
0.001 for MDA-MB-231, P < 0.001 for MCF-7, P = 0.001 for
T47D, P = 0.005 for MDA-MB-468, P = 0.01 for GI101) and
(except for GI101) TNC-16 (P < 0.001 for MDA-MB-231, P =
0.004 for MCF-7 and P = 0.002 for T47D). The TNC-14/16
isoforms also showed significantly higher MII than the TNC-L
transfectants, P < 0.01 for all cell lines. The MII was also sig-
nificantly higher with TNC-16 vs. TNC-L for MDA MB 231 (P
= 0.008), MCF-7 (P = 0.004), T47D (P = 0.009) and GI101
(P = 0.01) cells but not MDA MB 468 (Figure 4a).
In human breast carcinoma tissues, TNC-16 and/or TNC-14/
16 are not always detected alone, but frequently are seen in
combination with TNC-S [19]; therefore MCF-7 cells were co-
transfected with TNC-S and either TNC-16 or TNC-14/16.
The results showed that although TNC-16 and TNC-14/16
both enhanced MCF-7 cell MII, there was no additional effect
of co-expression of TNC-S (Figure 4b).
Increased breast cancer cell proliferation was observed in all
cell lines over-expressing TNC-L, TNC-16 and TNC-14/16.
This reached significance in MCF-7 cells for both TNC-16 and
TNC-14/16 (P = 0.023 and P = 0.002, respectively), and in
T47D cells for TNC-L and TNC-14/16 (P = 0.025 and P =
0.011, respectively; Figure 4c). A similar effect was seen in
MCF-7 cells co-transfected with TNC-S and either TNC-16 or
TNC-14/16 with no additive effect over the single isoforms
(Figure 4d).
Effect of fibroblast-associated tenascin-C expression on 
tumour cell invasion
The major source of TNC in breast carcinomas is the peri-
tumoural stroma [19], therefore we analysed the effect of
fibroblast-associated TNC isoform expression on tumour cell
invasion. Primary breast fibroblasts isolated from normal
breast tissue were transfected with individual TNC isoforms
and co-cultured in the lower chamber of invasion assays with
MCF-7 breast cancer cells. Standard invasion assays were
then carried out for each TNC isoform with vector-only con-
trols. There was some variability between donors in the capac-
ity of fibroblasts to promote tumour cell invasion (data not
shown). However, for all donors, a significantly higher MCF-7
MII was observed in the presence of fibroblasts over-express-
ing TNC-L, TNC-16 or TNC-14/16 (P < 0.001, Figure 5a) but
not in the presence of TNC-S. Furthermore, a higher MII for
MCF-7 cells was seen with fibroblasts over-expressing TNC-
16 or TNC-14/16 compared to TNC-L (P = 0.05 and P =
0.001, respectively). These results reflect the pattern seen
when the tumour cells themselves over-express TNC, and a
similar pattern also was seen in the presence of CM from
transfected primary fibroblasts (data not shown).
TNC is secreted by cells [31], so we investigated whether the
effect of fibroblast-associated TNC isoforms was mediated
directly through soluble TNC. CM from transfected fibroblasts
was added to the lower well of invasion assays containing
MCF-7 cells (Figure 5b) or GI101 cells (Figure 5c) with addi-
tion of blocking antibody to TNC (1 ng/ml BC-24) or equiva-
lent IgG1 control. This demonstrated inhibition of tumour cell
invasion to control levels, (cells transfected with vector only) orAvailable online http://breast-cancer-research.com/content/11/2/R24
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Figure 3
Confirmation of expression of tenascin-C isoforms Confirmation of expression of tenascin-C isoforms. (a) Endogenous expression of tenascin-C (TNC) isoforms in untransfected cell lines. Normalised 
relative expression of TNC isoforms were determined by reverse transcriptase polymerase chain reaction (RT-PCR) using primers and probes to 
invariant exon 17/18 boundary (Total TNC), the 9/16 (TNC-16) and 14/16 (TNC-14/16) exon boundary for breast cell lines ZR-75-1, MCF-7, T-47D, 
GI-101, Hs578T, MDA-MB-231, MDA-MB-436, MDA-MB-468 and melanoma cell line SKMel-28. Relative expression was calculated by compari-
son with standard curves derived from TNC-9-16 and TNC 9–14–16 recombinant clones to correct for differences in PCR efficiency for each TNC 
probe set normalised using level of housekeeping gene expression to correct for any differences in cellularity. (b) RT-PCR of primary fibroblasts and 
MCF-7 cells transiently transfected with TNC-S, TNC-L, TNC-16, TNC-14/16 and vector-only control (vector), using primers spanning the FN III 
alternatively spliced region (8F/18R). This shows appropriately sized bands in each of the cell populations, with no product in vector-only and non-
transfected MCF-7 controls, although there was evidence of low level expression of TNC-S in vector only and non-transfected fibroblast controls. (c) 
Immunohistochemistry for anti-Flag M2 antibody in MCF-7 cells transfected with TNC-L (left image) and for TNC (Monoclonal, BC24) in MCF-7 
transfected with vector control (right image). An average transfection efficiency of 35% was determined for each TNC isoform and staining con-
firmed that MCF-7 cells do not express TNC. (d) Western blot analysis for TNC in transiently transfected MCF-7 cells. This demonstrated a single 
species of TNC present in the whole cell lysate (WCL; i) and conditioned media (CM; ii) of transfected cells for each isoform. TNC-S is seen as a 
band at about 250 kDa, with slightly larger bands detected for TNC-16 and TNC 14/16, while TNC-L is detected at about 350 kDa.Breast Cancer Research    Vol 11 No 2    Hancox et al.
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lower for all MCF-7 transfected lines in the presence of TNC
antibody BC-24 and for all GI-101 cells other than those trans-
fected with TNC-16. This suggests that the pro-invasive effect
of TNC-transfected fibroblast CM is mediated directly through
secreted TNC.
Effect of tenascin-C isoforms on MMP expression and 
activity
To address whether TNC might mediate enhanced invasion
through up-regulation of MMP, invasion assays were per-
formed with the addition of the broad-spectrum MMP inhibitor
GM6001. This demonstrated a reduction in invasion of MCF-
7 cells under all conditions, both control and those transfected
with TNC isoforms (Figure 5d), indicating that invasion is
dependent on MMP activity but is not specifically TNC related.
MMP expression was investigated by TaqMan real-time RT-
PCR, ELISA for total enzyme activity and zymography for rela-
tive levels of active and latent enzyme in MCF-7 cells and hfff2
fibroblasts transiently transfected with TNC isoform con-
structs and control. A thorough analysis of 19 MMP family
members and all four TIMP members in MCF-7 [See Addi-
Figure 4
Direct effects of tenascin-C on tumour cell invasion Direct effects of tenascin-C on tumour cell invasion. (a) Invasion of MDA MB 231, MCF-7, T47D, MDA MB 468 and GI101 cell lines transfected 
with four different tenascin-C (TNC) isoform constructs and the vector alone. MDA-MB-231 and T47D cells transfected with TNC-L show a higher 
mean invasion index (MII) than controls (P < 0.05). All cell lines exhibited significantly higher MII with TNC-16 and TNC-14/16 compared with the 
vector alone (*P < 0.05, **P < 0.01, ***P < 0.001), other than GI101, which showed significantly higher invasion with TNC-14/16 only (P = 0.01). 
(b) Effect of co-transfection of TNC-S with either TNC-16 or TNC-14/16 isoforms on MCF-7 cell invasion. Both TNC-16 and TNC-14/16 led to an 
increased MCF-7 MII (*P < 0.01) compared with vector alone and other isoforms. However, there was no further enhancement in MII when the MCF-
7s were co-transfected with TNC-S and either TNC-16 or TNC-14/16 (ns = not significant). (c) Proliferation of MDA MB 231, MCF-7 and T47D cell 
lines transfected with four different TNC isoforms constructs and the vector alone. MBA-MB-231 cells exhibit no significant changes in proliferation 
when transfected with any of the isoforms. MCF-7 and T47D both show increased proliferation when transfected with TNC-14/16 compared with 
vector alone (*P < 0.05). MCF-7 exhibited an increase in proliferation with TNC-16 compared with vector alone, whereas T47Ds did not show any 
changes with TNC-16 but did have a significant (P < 0.05) increase in proliferation with TNC-L. (d) Effect of co-transfection of TNC-S with either 
TNC-16 or TNC-14/16 isoforms on MCF-7 cell proliferation. Both TNC-16 and TNC-14/16 lead to an increased MCF-7 proliferation (*P < 0.01) 
compared with vector alone and other isoforms. However, there was no further enhancement in proliferation when the MCF-7s were co-transfected 
with TNC-S and either TNC-16 or TNC-14/16 (ns = not significant). In all cases, the bars indicate the mean of at least three experiments with stand-
ard errors shown.Available online http://breast-cancer-research.com/content/11/2/R24
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tional data files 1, 2 and 3] and hfff2 (data not shown) revealed
that MMP-13 and TIMP-3 were upregulated two to fourfold rel-
ative to the vector but this was independent of the TNC iso-
form. None of the other MMPs or TIMPs analysed by real-time
PCR exhibited significant changes in expression in response
to TNC or were expressed at such low levels that any variation
in expression was likely to be non-significant [See Additional
data files 1, 2 and 3] MMPs 1 and 2 were undetectable in
MCF-7 cells and did not show any variation in hfff2 cells (data
not shown). ELISAs demonstrated no significant change in the
activity levels of MMP-1 or 2, while MMP9 was not detected in
MCF-7 or hfff2 by ELISA [See Additional data file 4]. Zymog-
raphy showed no change in MMP9 activation levels between
different clones when transfected into hfff2 [See Additional
data file 5] or MCF-7 cells (data not shown).
Discussion
The stromal microenvironment plays a critical role in determin-
ing tumour cell behaviour [32-34]. Changes in the matrix pro-
tein composition and extensive remodelling by proteolysis are
two key mechanisms by which the microenvironment can pro-
mote tumour progression [6,11,13,23].
Tenascin-C is a complex ECM protein that frequently is up-
regulated in the matrix around solid tumours [6,7]. The diverse
effects of TNC are mediated, in part, through the existence of
multiple alternatively spliced isoforms, which appear to be reg-
ulated in a strict temporal-spatial manner, implying a complex
structure-function relationship [13,35]. We previously have
shown that, in addition to a quantitative change in TNC in
breast cancer, there is a consistent change in the pattern of
TNC isoform expression, with induction of two additional iso-
Figure 5
Effect of fibroblast-associated tenascin-C expression on MCF-7 tumour cell invasion Effect of fibroblast-associated tenascin-C expression on MCF-7 tumour cell invasion. (a) Mean invasion index (MII) for MCF-7 tumour cell co-cul-
tured with primary breast fibroblasts (n = 5) transfected with tenascin-C (TNC) isoforms constructs or vector alone. Fibroblasts expressing TNC-16 
or TNC-14/16 significantly increased MII compared with TNC-L (P = 0.05 and P = 0.001, respectively), TNC-S and vector alone (***P < 0.001). 
Higher MII was also seen with fibroblast expressing TNC-L (P < 0.001) compared with TNC-S and vector alone. Bars indicate the mean of five 
donors, each measured in triplicate. (b) MCF-7 cell MII using conditioned media from primary breast fibroblasts transfected with TNC isoforms con-
structs or the vector alone in the presence of blocking TNC mouse monoclonal antibody BC-24 or equivalent IgG control. The blocking antibody sig-
nificantly reduced MII (*P < 0.05) independent of the TNC isoform. In all cases, the bars indicate the mean of three experiments with standard errors 
shown. (c) GI101 cell MII using conditioned media from fibroblasts transfected with TNC isoforms constructs or the vector alone in the presence of 
blocking TNC mouse monoclonal antibody BC-24 or equivalent IgG control. The blocking antibody significantly reduced MII (*P < 0.05, **P < 0.01) 
in all the cases except for TNC-16. In all cases, the bars indicate the mean of three experiments with standard errors shown. (d) MCF-7 cells trans-
fected with different TNC isoforms or vector only all exhibited significant reduction in MII in the presence of the matrix metalloproteinase inhibitor 
GM6001 (***P < 0.001). Bars indicate mean of three experiments.Breast Cancer Research    Vol 11 No 2    Hancox et al.
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forms – TNC-16 and TNC-14/16 – rarely detected in normal
resting breast [28]. In this study analysis of a series of breast
cancer cell lines demonstrated expression of TNC-16 and/or
TNC-14/16 in all oestrogen receptor (ER) negative lines char-
acterised by more aggressive behaviour [36], but not in the
ER-positive cell lines. We demonstrated that each of these
TNC isoforms increased breast cancer cell invasion signifi-
cantly and also enhanced tumour cell proliferation. The largest,
unspliced isoform TNC-L has been associated with a motile
phenotype most frequently [10,18,22] and, in keeping with
this, was found to promote invasion in this study. However, the
effect was significantly less than obtained with expression of
the tumour-associated TNC-14/16 isoforms and, in all but
GI101 cells, also with TNC-16. The fully spliced, adult-type
TNC-S had no effect on tumour cell invasion or proliferation,
consistent with its role as a component of normal basement
membrane in many tissues [22].
Inclusion of domains within the alternatively spliced FN III
region may alter the biological function of TNC through a
number of mechanisms. Some of the domains introduce new
adhesion motifs, for example, domain D (exon 14) contains a
binding site for α7β1 integrin [37], domains B and D interact
with the cell adhesion molecule F3/contactin [38], while the
A1-4/BD region binds to the cell surface receptor annexin II
[39]. Domains A3 and D also contain sites susceptible to pro-
teolytic cleavage [40] leading to generation of TNC fragments
that have been implicated in tumour progression [41]. Finally,
the alternatively spliced FN III region can also modify the inter-
action of TNC with other ECM proteins, specifically fibronectin
[42]. Thus, the precise structure of the TNC molecule deter-
mines the final biological effect.
The mechanism by which TNC-16 and TNC-14/16 promote
breast cancer cell invasion and proliferation is unclear,
although it does appear to require direct interaction between
the tumour cell and the protein, because the pro-invasive
effect was blocked by TNC antibody. Furthermore, the effect
of stromal-derived isoforms appear to be mediated through a
direct effect on the tumour cell rather than modification of
fibroblast function because the promotion of invasion by TNC-
transfected fibroblast CM was completely abrogated by anti-
TNC antibodies, suggesting that in transwell assays the solu-
ble TNC within the CM is acting as a chemoattractant mediat-
ing in the effect on invasion. These data imply a novel adhesive
interaction between TNC-16, TNC-14/16 and the breast can-
cer cells, although the nature of this currently is unclear. It is
unlikely that this interaction replicates the described interac-
tion between domain D (exon 14) and α7β1 on neurites [37],
because these breast cancer cells do not express α7 integrin
(unpublished data). It is interesting that TNC-L, which contains
both exons 14 and 16, does not promote invasion to the same
extent as the smaller isoforms. This is reminiscent of the inter-
play between domains identified in fibronectin. The central
Arg-Gly-Asp (RGD)-containing 120FN fragment of fibronectin
induces MMP expression in rabbit synovial fibroblasts, but
regions outside this domain inhibit this induction [43]. Thus it
is plausible that additional domains in the TNC-L protein coun-
teract the invasion-promoting effect of exons 14 and 16. Fur-
ther work using peptide fragments to investigate the
interactions between different domains of TNC would help dis-
sect these functions.
The actions of MMPs have been implicated in many aspects of
cancer progression including invasion, as a result of proteo-
lytic cleavage of MMPs and cell adhesion molecules [24,44],
and may influence tumour growth via release of matrix-bound
growth factors [45]. The importance of MMP activity in the sys-
tems used in this study is demonstrated by the significant
reduction of tumour cell invasion by a broad-spectrum MMP
inhibitor. This led us to investigate whether TNC-16 and TNC-
14/16 isoforms up-regulate MMP expression or activity. A rela-
tionship between TNC and MMP expression has been implied
in a number of studies, generally as a result of correlation of
expression levels or co-localisation in tissue studies [46,47].
There also is emerging evidence that TNC can modulate MMP
levels directly. Tremble and colleagues [27] showed that TNC
could increase MMP-1, 3 and 9 expression in rabbit synovial
fibroblasts, but only in collaboration with fibronectin and not if
added as a soluble protein. Kalembeyi and colleagues [25]
demonstrated up-regulation of MMP-9 expression in mouse
mammary carcinoma cells in response to exogenous TNC,
while a recent study reported that the invasion-promoting
effect of TNC on glioma cells is mediated through up-regula-
tion of MMP-12 [26].
In this study, an extensive analysis of MMP and TIMP expres-
sion revealed that TNC up-regulates MMP-13 and TIMP-3, but
that this is not specific to TNC-16 or TNC-14/16 isoforms,
with TNC-S, which does not generate enhanced tumour inva-
sion over control levels, also elevating expression levels to a
similar extent. Both MMP-13 and TIMP-3 have been implicated
in breast cancer [48]. Thus their induction by TNC may be of
relevance in vivo, although in the systems used in this study,
they do not appear to be specifically mediating the tumour-
promoter effect of TNC-16 and TNC-14/16. Furthermore, no
change in MMP activity, as revealed by zymographic analysis,
was seen in relation to different TNC isoforms. Thus, although
MMP activity is clearly required for invasion, these results sug-
gest that TNC-16 and TNC-14/16 mediate their action
through MMP-independent mechanisms. TNC has been
shown to up-regulate MMP in previous studies [25-27]; how-
ever, this difference may be due to a number of reasons: spe-
cies- and cell-type differences; the collaborating effect of other
MMPs; a three-dimensional environment compared with the
monolayer system used in this study [26]; and, of key impor-
tance, the nature of the TNC protein being investigated.
The precise nature of the TNC protein employed in previous
studies is unclear. However, if obtained commercially, as itAvailable online http://breast-cancer-research.com/content/11/2/R24
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appears to be in at least one of the studies, [26] it is likely to
represent a mixture of isoforms predominantly of the largest
splice variants and these could have quite distinct functions
from the isoforms used in the present study. Although we did
not demonstrate any interaction between TNC-S and TNC-16
or TNC-14/16 in co-transfection experiments, we did not
investigate the additional influence of TNC-L as this was less
frequently detected in the breast carcinoma tissues we ana-
lysed [19].
It is possible, and quite likely, that different TNC isoforms exert
their biological effects through different mechanisms. Thus
while it appears that many TNC species can influence MMP
expression, it is possible that TNC-16 and TNC-14/16 medi-
ate their effects on invasion and proliferation by signalling
through tumour cell adhesion receptors rather than through
MMP up-regulation. It is clear, however, that in the system
described in this study MMPs are a key requirement for tumour
invasion. The interplay of different factors in mediating a proc-
ess as complex as invasion is not surprising, and the inter-
dependence of multiple factors in this process has previously
been reported [31].
Conclusions
This study demonstrates a dual requirement for TNC and MMP
activity in breast cancer cell invasion and it confirms that the
tumour-associated TNC-16 and TNC-14/16 isoforms signifi-
cantly enhance this invasive process, even above the TNC-L
isoform traditionally associate with cell migration. The almost
universal and high level of expression of these isoforms in
breast carcinomas coupled with their largely tumour-restricted
distribution make them a plausible therapeutic target, a strat-
egy that already is being employed for tumour-restricted TNC
isoforms in other systems [49,50].
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